Thiocholesterol | 1249-81-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: Thiocholesterol
• 英文别名: Cholest-5-ene-3-thiol, (3beta)-；10,13-dimethyl-17-(6-methylheptan-2-yl)-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3-thiol
• CAS: 1249-81-6；80312-90-9
• 化学式: C₂₇H₄₆S
• mdl: MFCD00343997
• 分子量: 402.728
• InChiKey: QGVQZRDQPDLHHV-UHFFFAOYSA-N

物化性质

• 熔点：
  97-99 °C (lit.)
• 沸点：
  482.4±24.0 °C(Predicted)
• 密度：
  0.98±0.1 g/cm3(Predicted)
• 溶解度：
  氯仿（微溶）、二氯甲烷（微溶）、甲醇（微溶）
• LogP：
  11.330 (est)

计算性质

• 辛醇/水分配系数(LogP)：
  9.5
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  1
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• WGK Germany：
  3

文献信息

• Orally bioavailable lipid-based constructs
  申请人：SDG, Inc.

  公开号：US10751418B2

  公开（公告）日：2020-08-25

  The present invention is embodied by a composition capable of chaperoning a typically non-orally available therapeutic or diagnostic agent through the environment of the digestive tract such that the therapeutic or diagnostic agent is bioavailable. The composition may or may not be targeted to specific cellular receptors, such as hepatocytes. Therapeutic agents include, but are not limited to, insulin, calcitonin, serotonin, and other proteins. Targeting is accomplished with biotin or metal based targeting agents.

  本发明体现为一种组合物，它能够通过消化道环境对通常非口服的治疗剂或诊断剂进行陪衬，从而使治疗剂或诊断剂具有生物可利用性。该组合物可以针对或不针对特定的细胞受体，如肝细胞。治疗剂包括但不限于胰岛素、降钙素、血清素和其他蛋白质。生物素或金属靶向剂可实现靶向。
• Orally Bioavailable Lipid-Based Constructs
  申请人：Geho W. Blair

  公开号：US20100080773A1

  公开（公告）日：2010-04-01

  The present invention is embodied by a composition capable of chaperoning a typically non-orally available therapeutic or diagnostic agent through the environment of the digestive tract such that the therapetuic or diagnostic agent is bioavailable. The composition may or may not be targeted to specific cellular receptors, such as hepatocytes. Therapeutic agents include, but are not limited to, insulin, calcitonin, serotonin, and other proteins. Targeting is accomplished with biotin or metal based targeting agents.
• [EN] ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS<br/>[FR] CONSTRUCTIONS À BASE DE LIPIDES BIODISPONIBLES PAR VOIE ORALE
  申请人：SDG INC AN OHIO CORP

  公开号：WO2010111271A1

  公开（公告）日：2010-09-30

  The present invention is embodied by a composition capable of chaperoning a typically non-orally available therapeutic or diagnostic agent through the environment of the digestive tract such that the therapeutic or diagnostic agent is bioavailable. The composition may or may not be targeted to specific cellular receptors, such as hepatocytes. Therapeutic agents include, but are not limited to, insulin, calcitonin, serotonin, and other proteins. Targeting is accomplished with biotin or metal based targeting agents.
• [EN] OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF<br/>[FR] COMPOSITIONS D'OLIGONUCLÉOTIDES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：WAVE LIFE SCIENCES LTD

  公开号：WO2019200185A1

  公开（公告）日：2019-10-17

  Among other things, the present disclosure provides designed oligonucleotides, compositions, and methods of use thereof. In some embodiments, the present disclosure provides technologies useful for reducing levels of transcripts. In some embodiments, the present disclosure provides technologies useful for modulating transcript splicing. In some embodiments, provided technologies can alter splicing of a dystrophin (DMD) transcript. In some embodiments, the present disclosure provides methods for treating diseases, such as Duchenne muscular dystrophy, Becker's muscular dystrophy, etc.